Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 2/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13749512 | 1.00 | POLB (0.57) | POLBKMT2AMEN1PKMALDH1A1 | |
| SCHEMBL14445760 | 0.87 | POLB (0.54) | POLBKMT2AMEN1PKMALDH1A1 | |
| SCHEMBL8373692 | 0.85 | KMT2A (0.56) | KMT2AMEN1ALDH1A1GAACNR2 | |
| SCHEMBL26578388 | 0.81 | POLB (0.56) | POLBKMT2AALDH1A1ACACBMITF | |
| SCHEMBL6768253 | 0.81 | POLB (0.50) | POLBKMT2AMEN1PKMALDH1A1 | |
| SCHEMBL1049426 | 0.81 | APAF1 (0.46) | KMT2AMEN1 | |
| SCHEMBL653596 | 0.80 | APAF1 (0.62) | POLBKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL524374 | 0.80 | APAF1 (0.62) | POLBKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL157741 | 0.80 | APAF1 (0.62) | POLBKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL1816972 | 0.79 | SMN1; SMN2 (0.53) | POLBKMT2AMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026282-B1 | Peptide antagonists of the human urokinase receptor and method for selecting them | Cancerforskningsfonden AF 1989 (Fonden Til Fremme AF Exsperimentel Cancerforskning) (DK) | 2006-04-11 | — | — | US | claimed |
| WO-2000001802-A2 | PEPTIDE ANTAGONISTS OF THE HUMAN UROKINASE RECEPTOR AND METHOD FOR SELECTING THEM | CANCERFORSKNINGSFONDEN AF 1989 (FONDEN TIL FREMME AF EKSPERIMENTEL CANCERFORSKNING) (DK) | 2000-01-13 | — | — | WO | claimed |
| EP-4695271-A2 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | Merck Sharp & Dohme LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024215820-A2 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2024-10-17 | — | — | WO | disclosed |
| US-12023391-B2 | Alpha(v)beta(6) integrin-binding peptides and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240101601-A1 | BI-TERMINAL PEGYLATED INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230346960-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230183317-A1 | METHODS OF DETECTING AND TREATING LUNG DAMAGE IN RESPIRATORY-RELATED VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-15 | — | — | US | disclosed |
| US-11612663-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-28 | — | — | US | disclosed |
| EP-4146268-A2 | METHODS OF DETECTING AND TREATING LUNG DAMAGE IN RESPIRATORY-RELATED VIRAL INFECTIONS | The Regents of the University of California (US) | 2023-03-15 | — | — | EP | disclosed |
| US-11591369-B2 | Alpha(v)beta(6) integrin-binding peptides and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-28 | — | — | US | disclosed |
| WO-2007137196-A2 | TUBULIN BINDING ANTI CANCER COMPOUNDS AND PRODRUGS THEREOF | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20060160746-A1 | Amino acid and peptide conjugates of amiloride and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-07-20 | — | — | US | disclosed |
| US-7026282-B1 | Peptide antagonists of the human urokinase receptor and method for selecting them | Cancerforskningsfonden AF 1989 (Fonden Til Fremme AF Exsperimentel Cancerforskning) (DK) | 2006-04-11 | — | — | US | disclosed |
| WO-2005122379-A9 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | UNIV CALIFORNIA (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | disclosed |
| US-20050255042-A1 | On-demand cleavable linkers for radioconjugates for cancer imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER, UNIVERSITY OF CALIFORNIA (US) | 2005-11-17 | — | — | US | disclosed |
| US-20050256056-A1 | Peptide inhibitors of HIV | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA OFFICE OF TECHNOLOGY TRANSFER UNIVERSITY OF CALIFORNIA (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005056577-A2 | PEPTIDE INHIBITORS OF HIV | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-06-23 | — | — | WO | disclosed |
| WO-2000001802-A2 | PEPTIDE ANTAGONISTS OF THE HUMAN UROKINASE RECEPTOR AND METHOD FOR SELECTING THEM | CANCERFORSKNINGSFONDEN AF 1989 (FONDEN TIL FREMME AF EKSPERIMENTEL CANCERFORSKNING) (DK) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256056-A1 | Peptide inhibitors of HIV | VIP, NGLY1, PEPD | POLB 1305/4885KMT2A 4529/4885MEN1 1665/4885 |
| US-20230346960-A1 | PROTEOGLYCAN MIMETICS FOR ENHANCED WOUND HEALING, ANGIOGENESIS, AND VASCULAR REPAIR | PDGFA, PDGFRB, TEK | POLB 1146/4885KMT2A 4334/4885MEN1 4811/4885 |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | ITGA4, ITGB4, ITGA1 | POLB 4547/4885KMT2A 3460/4885MEN1 892/4885 |
| US-20230183317-A1 | METHODS OF DETECTING AND TREATING LUNG DAMAGE IN RESPIRATORY-RELATED VIRAL INFECTIONS | ACE2, ACE, MAVS | POLB 333/4885KMT2A 3529/4885MEN1 4500/4885 |
| US-20060160746-A1 | Amino acid and peptide conjugates of amiloride and methods of use thereof | VIP, SLC1A1, SLC1A3 | POLB 3597/4885KMT2A 2789/4885MEN1 465/4885 |
| US-11612663-B2 | Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair | PDGFA, PDGFRB, TEK | POLB 1146/4885KMT2A 4334/4885MEN1 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.